https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Oncology 2003;64(4):312-21
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Oncology 2003;64(4):312-212003-01-01 00:00:002003-01-01 00:00:00A Systemic Hyperthermia Oncologic Working Group trial. Ifosfamide, carboplatin, and etoposide combined with 41.8 degrees C whole-body hyperthermia for metastatic soft tissue sarcoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Oncology 2003;65 Suppl 2:76-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Oncology 2003;65 Suppl 2:76-92003-01-01 00:00:002003-01-01 00:00:00Ifosfamide with regional hyperthermia in soft-tissue sarcomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):174-80
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):174-802003-01-01 00:00:002020-06-23 09:43:48Influence of adjuvant hormone therapy and chemotherapy on the immune system analysed in the bone marrow of patients with breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):285-94
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Clin. Cancer Res. 2003 Jan;9(1):285-942003-01-01 00:00:002003-01-01 00:00:00Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Int. J. Cancer 2003 Jan;103(1):73-83
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Int. J. Cancer 2003 Jan;103(1):73-832003-01-01 00:00:002020-06-23 09:43:21Cognate interactions between memory T cells and tumor antigen-presenting dendritic cells from bone marrow of breast cancer patients: bidirectional cell stimulation, survival and antitumor activity in vivo
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Nat. Med. 2003 Jan;9(1):13-4
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Nat. Med. 2003 Jan;9(1):13-42003-01-01 00:00:002019-02-15 09:15:22Immunotherapy for AIDS virus infections: cautious optimism for cell-based vaccine
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Cancer Invest. 2003;21(6):873-86
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Cancer Invest. 2003;21(6):873-862003-01-01 00:00:002019-02-15 08:44:48The first 1000 dendritic cell vaccinees
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2003-01-01 / Curr. Top. Microbiol. Immunol. 2003;276:199-214
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2003-01-01 / Curr. Top. Microbiol. Immunol. 2003;276:199-2142003-01-01 00:00:002019-02-15 08:37:54Dendritic cell vaccination and viral infection–animal models
